Recursion Couples $200 Million Financing with Clinical and Partner Milestones

Company Recursion Pharmaceuticals; Sanofi Event Type Financing (Follow-On Offering) with Clinical Data and Partner Option Modality Small molecules (MEK1/2 inhibitor; RBM39 molecular-glue degrader); AI-enabled discovery Asset REC-4881; REC-1245; Sanofi-optioned oral dual-target immunology candidate Target MEK1/2; RBM39; undisclosed immunology targets Disease Area Familial adenomatous polyposis; endometrial…